nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—HTR1B—attention deficit hyperactivity disorder	0.784	1	CbGaD
Ondansetron—HTR4—brain—attention deficit hyperactivity disorder	0.00299	0.0607	CbGeAlD
Ondansetron—SLC47A2—nervous system—attention deficit hyperactivity disorder	0.00297	0.0601	CbGeAlD
Ondansetron—SLC47A2—central nervous system—attention deficit hyperactivity disorder	0.00286	0.0579	CbGeAlD
Ondansetron—SLC47A2—brain—attention deficit hyperactivity disorder	0.00227	0.046	CbGeAlD
Ondansetron—HTR3A—forebrain—attention deficit hyperactivity disorder	0.00195	0.0395	CbGeAlD
Ondansetron—OPRM1—forebrain—attention deficit hyperactivity disorder	0.00179	0.0362	CbGeAlD
Ondansetron—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00163	0.0331	CbGeAlD
Ondansetron—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00138	0.028	CbGeAlD
Ondansetron—HTR1A—forebrain—attention deficit hyperactivity disorder	0.00132	0.0267	CbGeAlD
Ondansetron—OPRM1—midbrain—attention deficit hyperactivity disorder	0.00118	0.0239	CbGeAlD
Ondansetron—KCNH2—forebrain—attention deficit hyperactivity disorder	0.00117	0.0238	CbGeAlD
Ondansetron—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.00112	0.0226	CbGeAlD
Ondansetron—HTR1B—midbrain—attention deficit hyperactivity disorder	0.00108	0.0219	CbGeAlD
Ondansetron—HTR3A—nervous system—attention deficit hyperactivity disorder	0.00106	0.0214	CbGeAlD
Ondansetron—SLC47A1—nervous system—attention deficit hyperactivity disorder	0.00104	0.021	CbGeAlD
Ondansetron—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.00102	0.0206	CbGeAlD
Ondansetron—SLC47A1—central nervous system—attention deficit hyperactivity disorder	0.001	0.0203	CbGeAlD
Ondansetron—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000993	0.0201	CbGeAlD
Ondansetron—SLC47A1—cerebellum—attention deficit hyperactivity disorder	0.000978	0.0198	CbGeAlD
Ondansetron—OPRM1—nervous system—attention deficit hyperactivity disorder	0.00097	0.0196	CbGeAlD
Ondansetron—OPRM1—central nervous system—attention deficit hyperactivity disorder	0.000933	0.0189	CbGeAlD
Ondansetron—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000887	0.018	CbGeAlD
Ondansetron—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000871	0.0176	CbGeAlD
Ondansetron—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000854	0.0173	CbGeAlD
Ondansetron—HTR3A—brain—attention deficit hyperactivity disorder	0.000808	0.0164	CbGeAlD
Ondansetron—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.000807	0.0163	CbGeAlD
Ondansetron—SLC47A1—brain—attention deficit hyperactivity disorder	0.000794	0.0161	CbGeAlD
Ondansetron—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000775	0.0157	CbGeAlD
Ondansetron—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000765	0.0155	CbGeAlD
Ondansetron—OPRM1—brain—attention deficit hyperactivity disorder	0.000741	0.015	CbGeAlD
Ondansetron—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000716	0.0145	CbGeAlD
Ondansetron—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000716	0.0145	CbGeAlD
Ondansetron—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000689	0.014	CbGeAlD
Ondansetron—HTR1B—brain—attention deficit hyperactivity disorder	0.000678	0.0137	CbGeAlD
Ondansetron—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000674	0.0137	CbGeAlD
Ondansetron—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000637	0.0129	CbGeAlD
Ondansetron—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000614	0.0124	CbGeAlD
Ondansetron—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.0006	0.0122	CbGeAlD
Ondansetron—HTR1A—brain—attention deficit hyperactivity disorder	0.000547	0.0111	CbGeAlD
Ondansetron—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000491	0.00995	CbGeAlD
Ondansetron—KCNH2—brain—attention deficit hyperactivity disorder	0.000487	0.00987	CbGeAlD
Ondansetron—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000473	0.00958	CbGeAlD
Ondansetron—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.000462	0.00936	CbGeAlD
Ondansetron—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000395	0.008	CbGeAlD
Ondansetron—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000389	0.00788	CbGeAlD
Ondansetron—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00038	0.00771	CbGeAlD
Ondansetron—CYP2E1—brain—attention deficit hyperactivity disorder	0.000375	0.0076	CbGeAlD
Ondansetron—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000374	0.00758	CbGeAlD
Ondansetron—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000366	0.00741	CbGeAlD
Ondansetron—CYP2D6—brain—attention deficit hyperactivity disorder	0.000297	0.00602	CbGeAlD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000132	0.000794	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000132	0.000793	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000131	0.00079	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00013	0.000784	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00013	0.000782	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000129	0.000774	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000129	0.000774	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000128	0.000771	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000126	0.00076	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000123	0.000737	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000122	0.000736	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000122	0.000731	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00012	0.000722	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00012	0.00072	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00012	0.00072	CbGpPWpGaD
Ondansetron—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000119	0.000714	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000116	0.000697	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000116	0.000697	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000114	0.000685	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000114	0.000685	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000114	0.000683	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000113	0.000677	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000113	0.000677	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000113	0.000677	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000112	0.000675	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000111	0.000669	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000109	0.000656	CbGpPWpGaD
Ondansetron—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000109	0.000653	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000108	0.000651	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.000651	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000107	0.000643	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000106	0.000637	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000106	0.000636	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000106	0.000635	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000106	0.000634	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000105	0.000631	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000105	0.000631	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000105	0.00063	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000105	0.00063	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000104	0.000627	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000104	0.000626	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000102	0.000615	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000101	0.000605	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.94e-05	0.000597	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.94e-05	0.000597	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.94e-05	0.000597	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.83e-05	0.000591	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.81e-05	0.00059	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	9.81e-05	0.00059	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	9.65e-05	0.00058	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.63e-05	0.000579	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.35e-05	0.000562	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.34e-05	0.000562	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	9.26e-05	0.000556	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	9.17e-05	0.000551	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	9.15e-05	0.00055	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	9.12e-05	0.000548	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.02e-05	0.000542	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.84e-05	0.000531	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.69e-05	0.000522	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.68e-05	0.000522	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.66e-05	0.00052	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.58e-05	0.000516	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.58e-05	0.000515	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.51e-05	0.000512	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.48e-05	0.00051	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.42e-05	0.000506	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	8.33e-05	0.000501	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.31e-05	0.0005	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.27e-05	0.000497	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.17e-05	0.000491	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.99e-05	0.00048	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	7.83e-05	0.000471	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	7.83e-05	0.000471	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	7.66e-05	0.00046	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.61e-05	0.000457	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	7.56e-05	0.000455	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.51e-05	0.000451	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.47e-05	0.000449	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.45e-05	0.000448	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.44e-05	0.000447	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.4e-05	0.000445	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.39e-05	0.000444	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.35e-05	0.000442	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.35e-05	0.000442	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	7.35e-05	0.000442	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.34e-05	0.000441	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.8e-05	0.000408	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	6.77e-05	0.000407	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.76e-05	0.000406	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.67e-05	0.000401	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.58e-05	0.000395	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	6.55e-05	0.000394	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.48e-05	0.00039	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.45e-05	0.000387	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	6.44e-05	0.000387	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.42e-05	0.000386	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	6.36e-05	0.000382	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.36e-05	0.000382	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.34e-05	0.000381	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.32e-05	0.00038	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.31e-05	0.000379	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.27e-05	0.000377	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	6.15e-05	0.000369	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.97e-05	0.000359	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.97e-05	0.000359	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.95e-05	0.000358	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.93e-05	0.000356	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.85e-05	0.000352	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.83e-05	0.000351	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.83e-05	0.000351	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.81e-05	0.000349	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.78e-05	0.000348	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.78e-05	0.000347	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.76e-05	0.000346	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.69e-05	0.000342	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.69e-05	0.000342	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.62e-05	0.000337	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.6e-05	0.000336	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.58e-05	0.000335	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.55e-05	0.000333	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.42e-05	0.000326	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.38e-05	0.000324	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.33e-05	0.00032	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.25e-05	0.000316	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.23e-05	0.000314	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.16e-05	0.00031	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.16e-05	0.00031	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.1e-05	0.000306	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.04e-05	0.000303	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.01e-05	0.000301	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.99e-05	0.0003	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.91e-05	0.000295	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.91e-05	0.000295	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.91e-05	0.000295	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.87e-05	0.000293	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.85e-05	0.000291	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.84e-05	0.000291	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.82e-05	0.000289	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.75e-05	0.000286	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.68e-05	0.000281	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.53e-05	0.000273	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.52e-05	0.000271	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.47e-05	0.000269	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.46e-05	0.000268	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.4e-05	0.000265	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.33e-05	0.00026	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.32e-05	0.000259	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.15e-05	0.00025	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	4.12e-05	0.000248	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.12e-05	0.000248	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.1e-05	0.000246	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	4.06e-05	0.000244	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.94e-05	0.000237	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.77e-05	0.000227	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.77e-05	0.000227	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.66e-05	0.00022	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.63e-05	0.000218	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.52e-05	0.000211	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.46e-05	0.000208	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.45e-05	0.000207	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.41e-05	0.000205	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.4e-05	0.000205	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.33e-05	0.0002	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.3e-05	0.000198	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.2e-05	0.000193	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.18e-05	0.000191	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.16e-05	0.00019	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.14e-05	0.000189	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.1e-05	0.000186	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.07e-05	0.000184	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.05e-05	0.000183	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.04e-05	0.000183	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.01e-05	0.000181	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.99e-05	0.000179	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.99e-05	0.000179	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	2.98e-05	0.000179	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.98e-05	0.000179	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.97e-05	0.000179	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.94e-05	0.000177	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	2.93e-05	0.000176	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.87e-05	0.000173	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.82e-05	0.00017	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.81e-05	0.000169	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.77e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.73e-05	0.000164	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.73e-05	0.000164	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.68e-05	0.000161	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.63e-05	0.000158	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.6e-05	0.000156	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.6e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	2.5e-05	0.00015	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	2.48e-05	0.000149	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.42e-05	0.000146	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.39e-05	0.000143	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.38e-05	0.000143	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.27e-05	0.000137	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.27e-05	0.000136	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.23e-05	0.000134	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.12e-05	0.000127	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.12e-05	0.000127	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	2.1e-05	0.000126	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.1e-05	0.000126	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.08e-05	0.000125	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	2.07e-05	0.000124	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.01e-05	0.000121	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.97e-05	0.000118	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.94e-05	0.000116	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.92e-05	0.000115	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	1.81e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	1.81e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.8e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.8e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.8e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	1.79e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.77e-05	0.000106	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.7e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.69e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.68e-05	0.000101	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.64e-05	9.87e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.61e-05	9.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.6e-05	9.61e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.44e-05	8.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.39e-05	8.33e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.39e-05	8.33e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.37e-05	8.21e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.36e-05	8.19e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.28e-05	7.72e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.27e-05	7.66e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	1.27e-05	7.65e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.27e-05	7.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	1.26e-05	7.59e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.23e-05	7.37e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.18e-05	7.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.11e-05	6.66e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.09e-05	6.54e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.08e-05	6.49e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	1.07e-05	6.44e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.05e-05	6.34e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.05e-05	6.29e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.04e-05	6.26e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.99e-06	5.4e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.39e-06	5.04e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.33e-06	5.01e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	7.76e-06	4.66e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	7.74e-06	4.65e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	5.51e-06	3.31e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	5.46e-06	3.28e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	4.66e-06	2.8e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.6e-06	2.16e-05	CbGpPWpGaD
